Demonstration of CDX2 is highly antibody dependant

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 1, 2013, Pages 64-72

  Borrisholt, Martine ^a   Nielsen, Søren ^a   Vyberg, Mogens ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

antibody clone; CDX2; external quality control; laboratory proficiency; protocol optimization

Indexed keywords

ANTIBODY; CDX2 88 ANTIBODY; DAK CDX2 ANTIBODY; EPR2764Y ANTIBODY; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMATOID CARCINOMA; SENSITIVITY ANALYSIS; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; DENMARK; DIAGNOSIS, DIFFERENTIAL; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL NEOPLASMS; LUNG NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; QUALITY CONTROL; QUALITY IMPROVEMENT; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871982705     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318257f8aa     Document Type: Article

References (51)

1. Suh E, Traber PG. An intestine-specific homeobox gene regulates proliferation and differentiation. Mol Cell Biol. 1996;16:619-625. (Pubitemid 26029101)
2. Drummond F, Putt W, Fox M, et al. Cloning and chromosome assignment of the human CDX2 gene. Ann Hum Genet. 1997;5:393-400. (Pubitemid 28040820)
3. Liu Q, The M, Ito K, et al. CDX2 expression is progressively decreased in human gastric intestinal metaplasia, dysplasia and cancer. Mod Pathol. 2007;20:1286-1297. (Pubitemid 350126854)
4. Moskaluk CA, Zhang H, Powell SM, et al. CDX2 protein expression in normal and malignant human tissues: an immunohis-tochemical survey using tissue microarrays. Mod Pathol. 2003; 16:913-919. (Pubitemid 37152021)
5. Barbareschi M, Murer B, Colby TV, et al. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol. 2003;27:141-149. (Pubitemid 36152222)
6. Phillips RW, Frierson HF Jr, Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol. 2003;11:1442-1447. (Pubitemid 37315196)
7. Sung MT, Lopez-Beltran A, Eble JN, et al. Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. Mod Pathol. 2006;11:1395-1401. (Pubitemid 44624156)
8. Mazziotta RM, Borczuk AC, Powell CA, et al. CDX2 immunos-taining as a gastrointestinal marker. Appl Immunohistochem Mol Morphol. 2005;13:55-60.
9. Overman MJ, Pozadzides J, Kopetz S, et al. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer. 2010;102:144-150.
10. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin. Am J Surg Pathol. 2003;27:303-310.
11. Zhang MQ, Lin F, Hui P, et al. Expression of mucins, SIMA, villin, and CDX2 in small-intestinal adenocarcinoma. Am J Clin Pathol. 2007;128:808-816. (Pubitemid 350133993)
12. Bakaris S, Cetinkaya A, Ezberci F, et al. Expression of homeo-domain protein CDX2 in colorectal adenoma and adenocarcinoma. Histol Histopathol. 2008;23:1043-1047.
13. De Lott LB, Morrison C, Suster S, et al. CDX2 is a useful marker of intestinal-type differentiation. Arch Pathol Lab Med. 2005;129: 1100-1105.
14. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11:3766-3772. (Pubitemid 40685594)
15. Kaimaktchiev V, Terracciano L, Tornillo L, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol. 2004;17:1392-1399. (Pubitemid 39472995)
16. Baba Y, Nosho K, Shima K, et al. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res. 2009;15:4665-4673.
17. Hinoi T, Tani M, Lucas PC, et al. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol. 2001;159:2239-2248. (Pubitemid 33104277)
18. Winn B, Tavares R, Fanion J, et al. Differentiating the indiffer-entiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation. Hum Pathol. 2009;40:398-404.
19. Almeida R, Silva E, Santos-Silva F, et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol. 2003;199:36-40. (Pubitemid 36054727)
20. O'Connell FP, Wang HH, Odze RD. Utility of immunohistochem-istry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract. Arch Pathol Lab Med. 2005;129:338-347. (Pubitemid 40343988)
21. Logani S, Oliva E, Arnell PM, et al. Use of novel immunohisto-chemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol. 2005;18:19-25. (Pubitemid 40128090)
22. Vang R, Gown AM, Wu LSF, et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol. 2006;19:1421-1428. (Pubitemid 44624160)
23. Ortiz-Rey JA, Alvarez C, San Miguel P, et al. Expression of CDX2, cytokeratins 7 and 20 in sinonasal intestinal-type adenocarcinoma. Appl Immunohistochem Mol Morphol. 2005;13:142-146. (Pubitemid 40726850)
24. Bhaijee F, Carron J, Bell D. Low-grade nonintestinal sinonasal adenocarcinoma: a diagnosis of exclusion. Ann Diagn Pathol. 2011;15:181-184.
25. Suh N, Yang XJ, Tretiakova MS, et al. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol. 2005;18:1217-1222. (Pubitemid 43079921)
26. Paner GP, McKenney JK, Barkan GA, et al. Immunohistochemical analysis in a morphologic spectrum of urachal epithelial neoplasms: diagnostic implications and pitfalls. Am J Surg Pathol. 2011;35:787-798.
27. Barbareschi M, Roldo C, Zamboni G, et al. CDX-2 homeobox gene product expression in neuroendocrine tumors. Am J Surg Pathol. 2004;28:1169-1179.
28. Erickson LA, Papouchado B, Dimashkieh H, et al. CDX2 as a marker for neuroendocrine tumors of unknown primary site. Endocr Pathol. 2004;15:247-252. (Pubitemid 40169418)
29. Jaffee IM, Rahmani M, Singhal MG, et al. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin. Arch Pathol Lab Med. 2006;130:1522-1526. (Pubitemid 44520720)
30. Saqi A, Alexis D, Remotti F, et al. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Surg Pathol. 2005;123:394-404. (Pubitemid 40315081)
31. Chu PG, Schwarz RE, Lau SK, et al. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma. Am J Surg Pathol. 2005;29:359-367. (Pubitemid 40321972)
32. Saad RS, Ismiil N, Dube V, et al. CDX-2 expression is a common event in primary intestinal-type endocervical adenocarcinoma. Am J Clin Pathol. 2009;132:531-538.
33. Sullivan LM, Smolkin ME, Frierson HF, et al. Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas. Am J Surg Pathol. 2008;32:1608-1612.
34. Bing Z, Pasha T, Tomaszewski JE, et al. CDX2 expression in yolk sac component of testicular germ cell tumors. Int J Surg Pathol. 2009;17:373-377.
35. Yatabe Y, Koga T, Mitsudomi T, et al. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol. 2004;203:645-652. (Pubitemid 38714101)
36. Rossi G, Marchioni A, Romagnani E, et al. Primary lung cancer presenting with gastrointestinal tract involvement: clinicopathologic and immunohistochemical features in a series of 18 consecutive cases. J Thorac Oncol. 2007;2:115-120. (Pubitemid 47181338)
37. Strickland-Marmol LB, Khoor A, Livingston SK, et al. Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarci-nomas to the brain. Arch Pathol Lab Med. 2007;131:1686-1690. (Pubitemid 350077466)
38. Houghton O, Connolly LE, McCluggage WG. Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2. Histopathology. 2008;53:156-165. (Pubitemid 352032773)
39. Adley BP, Maxwell K, Dalton DP, et al. Urothelial-type adeno-carcinoma of the prostate mimicking metastatic colorectal adeno-carcinoma. Int Braz J Urol. 2006;32:681-687. (Pubitemid 46138856)
40. Leite KR, Mitteldorf CA, Srougi M, et al. Cdx2, cytokeratin 20, thyroid transcription factor 1, and prostate-specific antigen expression in unusual subtypes of prostate cancer. Ann Diagn Pathol. 2008;12:260-266.
41. http://www.nordiqc.org/Run-27-B8-C2/Assessment/assessment-27-CDX2.htm.
42. Available at: http://www.webcitation.org/60RaNqrY7. Accessed July 25, 2011.
43. http://www.cellmarque.com/cmc/P-antibodydetail.php?id = 2025.
44. Available at: http://www.webcitation.org/60Rb5MnQP. Accessed July 25, 2011.
45. http://www.dako.com/us/download.pdf?objectid=118787001.
46. Available at: http://www.webcitation.org/60Ray4dwv. Accessed July 25, 2011.
47. http://www.leica-microsystems.com/fileadmin/img-uploads/novoc astra-reagents/Novocastra-datasheets/cdx2.pdf.
48. Available at: http://www.webcitation.org/60RafgPJ7. Accessed July 25, 2011.
49. http://www.biogenex.com/int-doc/DS-English/932-392M-EN12492926 79.pd.
50. Available at: http://www.webcitation.org/60Rb1yOmb. Accessed July 25, 2011.
51. Tornillo L, Moch H, Diener PA, et al. CDX-2 immunostaining in primary and secondary ovarian carcinomas. J Clin Pathol. 2004; 57:641-643. (Pubitemid 38725768)